Person: ŞENOL, KAZIM
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
ŞENOL
First Name
KAZIM
Name
15 results
Search Results
Now showing 1 - 10 of 15
Publication Clinical features and short-term outcomes of bariatric surgery in morbidly obese patients: Institutional experience at a rural hospital(Mary Ann Liebert, Inc, 2021-03-01) Şenol, Kazım; Ferhatoğlu, Murat Ferhat; Kocaeli, Aysen Akkurt; Dündar, Halit Ziya; Kaya, Ekrem; ŞENOL, KAZIM; DÜNDAR, HALİT ZİYA; KAYA, EKREM; Tıp Fakültesi; Genel Cerrahi Ana Bilim Dalı; 0000-0002-9562-4195; FVY-2168-2022; EWI-3634-2022; AAG-7319-2021Objective: To prospectively evaluate the postoperative morbidity, mortality, and weight loss evolution of patients who underwent a bariatric procedure during 1 year of follow-up.Methods: Since July 2016, a total of 101 patients' data have been prospectively registered in a database. Comorbidities, operating time, hospital stay, early and late complications rate, and weight loss evolution after 1 year of follow-up were recorded.Results: The mean age was 38.41 +/- 11.05 years with a mean body mass index (BMI) of 49.02 +/- 5.89 kg/m(2) (range 38-67). Laparoscopic sleeve gastrectomy (LSG) was performed in 93 patients (92.07%) and Roux-en-Y gastric bypass (RNYGB) in 8 patients (7.92%). Thirty-day morbidity rate was 7.92% (8/101). Within a mean 9.32 +/- 2.25 (range 1-19) months follow-up time, mean percent of the excess of weight loss of 1st, 6th, and 12th months were 22.7 +/- 6.1, 67.2 +/- 11.2, and 81.4 +/- 10.5, respectively. Diabetes (n = 38, 37.6%), hypertension (n = 13, 12.9%), and obstructive sleep apnea (n = 5, 4.9%) were resolved in 76%, 68.4%, and 100% of the patients, respectively (p < 0.001).Conclusions: LSG and RNYGB are safe and highly effective, particularly in patients with a BMI >50 kg/m(2). Both techniques have been presented with better clinical outcomes regarding significant comorbidity resolution in the early evolution of weight loss.Publication Metastatic neoplasms to the breast(Sage Publications Inc, 2023-10-29) Özsen, Mine; Tolunay, Şahsine; Polatkan, Seyit Ali Volkan; Şenol, Kazım; Gökgöz, Mustafa Şehsuvar; ÖZŞEN, MİNE; TOLUNAY, ŞAHSİNE; POLATKAN, SEYİT ALİ VOLKAN; ŞENOL, KAZIM; GÖKGÖZ, MUSTAFA ŞEHSUVAR; Tıp Fakültesi; Patoloji Ana Bilim Dalı; 0000-0001-6273-0664; JIT-5311-2023; AAI-1612-2021; FSB-8576-2022; KGQ-4411-2024; EWY-5692-2022Objective: When the clinical presentation is related to the metastatic mass and a radiologically solitary tumor focus is detected, especially in cases where clinical information is not taken into account or is insufficient, if a possible metastatic neoplasia is not kept in mind then it is possible to evaluate the tumor as a primary breast neoplasm. In this study, it is aimed to present our cases of non-hematopoietic metastatic neoplasms and to evaluate the clinicopathological features that may aid in distinguishing metastatic from primary neoplasms. Material and Methods: This study includes cases diagnosed with metastatic non-hematopoietic breast neoplasm in breast resection materials in our center, between the years 2010-2023. All cases were analyzed retrospectively by evaluating clinicopathological features. Results: Of the 15 subjects included in the study, 11 (73%) were female and 4 (27%) were male. The mean age of the patients were 46.9 ranged from 22 to 63 years. The most frequent metastatic malignancy was carcinoma (60%), followed by melanoma (33%) and sarcoma (7%). Of the 9 patients with metastatic carcinoma, the primary tumor originated from the lungs in 4, from gastrointestinal system in 2, female genital tract in 2, and kidney in 1 patient. Sarcoma diagnosis was given in a single patient and the histology was a leiomyosarcoma originating from kidney. Conclusion: A careful histomorphological and immunohistochemical evaluation and a detailed examination of the clinicoradiological data are critical to establish the right course in patient management, treatment plan and to correctly predict the prognosis.Publication A multicenter study of genotype variation/demographic patterns in 2475 individuals including 1444 cases with breast cancer in Turkey(Galenos Yayınevi, 2023-07-01) Boğa, İbrahim; Sağ, Şebnem Özemri; Duman, Nilgün; Özdemir, Sevda Yeşim; Ergören, Mahmut Çerkez; Dalcı, Kubilay; Mujde, Cem; Parsak, Cem Kaan; Rencuzoğullari, Çağla; Sönmezler, Özge; Yalav, Orçun; Alemdar, Adem; Aliyeva, Lamiya; Bozkurt, Özlem; Çetintaş, Sibel; Çubukcu, Erdem; Deligönül, Adem; Doğan, Berkcan; Ergüzeloğlu, Cemre Örnek; Evrensel, Türkkan; Gökgöz, Şehsuvar; Şenol, Kazım; Tolunay, Şahsine; Akyürek, Esra; Başgöz, Neslihan; Gökçe, Nuriye; Dündar, Bilge; Öztürk, Figen; Taşkın, Duygu; Demirtaş, Mercan; Çağ, Murat; Diker, Ömer; Olgun, Polat; Bozdoğan, Sevcan Tuğ; Dündar, Munis; Bişgin, Atıl; Temel, Şehime Gülsün; ÖZEMRİ SAĞ, ŞEBNEM; ALIYEVA, LAMIYA; DOĞAN, BERKCAN; TEMEL, ŞEHİME GÜLSÜN; ALEMDAR, ADEM; Ergüzeloğlu, Cemre Örnek; EVRENSEL, TÜRKKAN; BOZKURT, ÖZLEM; TOLUNAY, ŞAHSİNE; ÇETİNTAŞ, SİBEL; ÇUBUKÇU, ERDEM; DELİGÖNÜL, ADEM; GÖKGÖZ, MUSTAFA ŞEHSUVAR; ŞENOL, KAZIM; Tıp Fakültesi; Tıbbi Onkoloji Ana Bilim Dalı; 0000-0001-8061-8131 ; IYV-1877-2023; CCG-4609-2022; AAD-5249-2020; IRT-7350-2023; HIZ-7332-2022; EXQ-7887-2022; EXZ-0745-2022; IJL-9778-2023; AAI-1612-2021; EOI-5652-2022; ETP-1691-2022; ESM-4544-2022; EXK-4525-2022; KGQ-4411-2024; GZC-2526-2022Objective: Breast cancer (BC) is the most common cancer type in women and may be inherited, mostly in an autosomal dominant pattern. The clinical diagnosis of BC relies on the published diagnostic criteria, and analysis of two genes, BRCA1 and BRCA2, which are strongly associated with BC, are included in these criteria. The aim of this study was to compare BC index cases with non-BC individuals in terms of genotype and diagnostic features to investigate the genotype/demographic information association. Materials and Methods: Mutational analyses for the BRCA1/BRCA2 genes was performed in 2475 individuals between 2013-2022 from collaborative centers across Turkey, of whom 1444 with BC were designated as index cases.Results: Overall, mutations were identified in 17% (421/2475), while the percentage of mutation carriers in cases of BC was similar, 16.6% (239/1444). BRCA1/BRCA2 gene mutations were detected in 17.8% (131/737) of familial cases and 12% (78/549) of sporadic cases. Mutations in BRCA1 were found in 4.9%, whereas 12% were in BRCA2 (p<0.05). Meta-analyses were performed to compare these results with other studies of Mediterranean-region populations.Conclusion: Patients with BRCA2 mutations were significantly more common than those with BRCA1 mutations. In sporadic cases, there was a lower proportion with BRCA1/BRCA2 variants, as expected, and these results were consistent with the data of Mediterranean-region populations. However, the present study, because of the large sample size, revealed more robust findings than previous studies. These findings may be helpful in facilitating the clinical management of BC for both familial and non-familial cases.Publication Combined analysis of the mf18-02/03 neosentiturk studies: Factors predicting recurrence in ycn0/ypn-positive breast cancer with sentinel lymph node biopsy - or targeted axillary dissection - alone after neoadjuvant chemotherapy(Springer, 2023-06-01) Çabioğlu, Neslihan; Müslümanoğlu, Mahmut; Igcı, Abdullah; Karanlık, Hasan; Tükenmez, Mustafa; Gülçelik, Mehmet Ali; Koçer, Havva Belma; Çakmak, Güldeniz Karadeniz; Yıldırım, Nilufer; Emiroğlu, Selman; Akgül, Giray; Ilgün, Serkan; Zengel, Baha; Can-Trabulus, Didem; Uğurlu, Ümit; Uras, Cihan; Akcan, Alper Celal; Yormaz, Serdar; Ersoy, Yeliz Emine; Özbaş, Serdar; Dilege, Ece; Citgez, Bülent; Bölükbaşı, Yasemin; Altınok, Ayşe; Özkurt, Enver; Dağ, Ahmet; Başaran, Gül; Utkan, Zafer; Özçınar, Beyza; Arıcı, Cumhur; El Jorani, Isra; Kara, Halil; Yiğit, Banu; Sen Oran, Ebru; Erozgen, Fazilet; Soyder, Aykut; Çelik, Burak; Polat, Ayfer; Zer, Leyla; Sakman, Gürhan; Yeniay, Levent; Velidedeoglu, Mehmet; Atahan, Kemal; Varol, Ecenur; Göktepe, Berk; Veliyeva, Vefa; Soran, Atilla; Ibis, Kamuran; Özmen, Vahit; El Jorani, Isra; Senol, Kazım; ŞENOL, KAZIM; Tıp Fakültesi; Genel Cerrahi Ana Bilim Dalı; KGQ-4411-2024Publication The positive effects of the human amniotic membrane on the healing of staple line after sleeve gastrectomy applied long-evans rat model(Springer, 2019-11-01) Ferhatoğlu, Murat Ferhat; Kıvılcım, Taner; Şenol, Kazım; Vural, Gürcan; Kartal, Abdulcabbar; İncir, Said; Filiz, Ali İlker; Kebudi, Abut; ŞENOL, KAZIM; Tıp Fakültesi; Genel Cerrahi Ana Bilim Dalı; 0000-0001-6273-0664; KGQ-4411-2024Background The staple line leakage is a dangerous complication of sleeve gastrectomy. Various strategies have been tried to reduce the leakage risk. The amniotic membrane (AmM) is the inner layer of the placental membranes and has anti-inflammatory, anti-fibrosis, and anti-scarring effects, and it also has lower immune characteristics which are another essential characteristic of AmM concerning its utility for grafting. In this study, we aimed to investigate the impact of AmM on the staple line healing process of sleeve gastrectomy model in rats. Materials and Methods We used twenty-eight Long-Evans rats in this study. Sleeve gastrectomy was performed with tristapler. Fourteen rats served as controls, AmM was applied staple line of the other fourteen. Fourteen animals were sacrificed (seven from the AmM applied group and the other seven from the control group) on the third postoperative day. And, the other fourteen animals were sacrificed (seven from the AmM applied group and seven from the control group) on the seventh postoperative day. The tissue around the staple line was evaluated microscopically and macroscopically, bursting pressures and hydroxyproline levels were also measured. Results The bursting pressure and hydroxyproline measurements of the AmM applied group was significantly higher on the seventh postoperative day (p = 0.015, p = 0.012) Fibroblast activity and neoangiogenesis of the AmM applied group was also significantly higher on the seventh postoperative day (p = 0.004, p = 0.002). Conclusion This study showed that covering of staple line of sleeve gastrectomy model in rats significantly provided higher bursting pressures and increased hydroxyproline levels, fibroblast activity, and neoangiogenesis which may potentially lead a better staple line healing. We think further investigations are needed on this issue.Publication Sentinel lymph node biopsy with/without axillary dissection in clinically node-positive breast cancer after neoadjuvant chemotherapy(Springer, 2022-04-01) Cabioğlu, Neslihan; Karanlık, Hasan; Gülçelik, Mehmet Ali; Ilgün, Serkan; Igcı, Abdullah; Uraş, Cihan; Cakmak, Güldeniz Karadeniz; Uğurlu, Umit; Müslümanoğlu, Mahmut; Koçer, Havva Belma; Trabulus, Didem Can; Dağ, Ahmet; Tükenmez, Mustafa; Sen Oran, Ebru; Karaman, Niyazi; Emiroğlu, Selman; Zengel, Baha; Atahan, Kemal; Ersoy, Yeliz; Dilege, Ece; Doğan, Lütfi; Başaran, Gül; Yıldırım, Nilüfer; Kara, Halil; Özbas, Serdar; Soyder, Aykut; Polat, Ayfer Kamali; Özemir, Ibrahim Ali; Yeniay, Levent; Altinok, Ayşe; Doğan, Mutlu; Özkurt, Enver; Velidedeoğlu, Mehmet; Özçınar, Beyza; Balcı, Fatih Levent; Sevinç, Ali Ibrahim; Arıcı, Cumhur; Özmen, Vahit; Şenol, Kazım; ŞENOL, KAZIM; Tıp Fakültesi; Genel Cerrahi Ana Bilim Dalı; KGQ-4411-2024Publication Identification of CHEK2 germline mutations in BRCA1/2- and PALB2-negative breast and ovarian cancer patients(Karger, 2022-08-01) Aksoy, Fuat; Tezcan Ünlü, Havva; Çeçener, Gülşah; Güney Eskiler, Gamze; Egeli, Ünal; Tunca, Berrin; Efendi Erdem, Ecem; Şenol, Kazım; Gökgöz, Mustafa Şehsuvar; AKSOY, FUAT; Tezcan Ünlü, Havva; ÇEÇENER, GÜLŞAH; EGELİ, ÜNAL; TUNCA, BERRİN; Efendi Erdem, Ecem; ŞENOL, KAZIM; GÖKGÖZ, MUSTAFA ŞEHSUVAR; Tıp Fakültesi; Genel Cerrahi Ana Bilim Dalı; 0000-0001-5808-9384; 0000-0002-0910-4258; 0000-0002-3820-424X; 0000-0001-7904-883X; 0000-0002-1619-6680; 0000-0001-6273-0664; HII-8895-2022; AAP-9988-2020; GYU-0252-2022; AAH-1420-2021; ABI-6078-2020; GWP-6104-2022; KGQ-4411-2024; EWY-5692-2022Introduction: The CHEK2 gene is known to be an important signal transducer involved in DNA repair, apoptosis, or cell cycle arrest in response to DNA damage. The mutations in this gene have been associated with a wide range of cancers, both sporadic and hereditary. Germline CHEK2 mutations are linked to an increased risk of breast cancer. Therefore, the aim of this study was to identify the prevalence of CHEK2 variants in BRCA1/2- and PALB2-negative early-onset patients with breast cancer and/or ovarian cancer in a Turkish population for the first time. Methods: The study included 95 patients with BRCA1/2- and PALB2-negative early-onset breast cancer and/or ovarian cancer and also 60 unaffected women. All the intron/exon boundaries and coding exons of CHEK2 were subjected to mutational analysis by heteroduplex analysis and DNA sequencing. Results: A total of 16 CHEK2 variants were found in breast cancer patients within the Turkish population. CHEK2 c.1100delC mutation most frequently studied in the CHEK2 gene was not detected in our study. The prevalence of variants of uncertain significance in CHEK2 was found to be 7.3% (n = 7) in BRCA1/2 and PALB2 mutation-negative Turkish patients with early-onset breast and/or ovarian cancer. Conclusion: The present study may shed light on alternative variations that could be significant for understanding the prevalence and clinical suitability of the CHEK2 gene.Publication Aso visual abstract: Intervention for hepatic and pulmonary metastases in breast cancer patients-prospective, multi-institutional registry study: Imet; protocol mf 14-02(Springer, 2022-08-06) Soran, Atilla; Özbaş, S.; Özcınar, B.; Isık, A.; Doğan, L.; Dağ, A.; Karanlık, H.; Aytaç, O.; Karadeniz Çakmak, G.; Dalcı, K.; Doğan, M.; Sezer, Y. A.; Özyar, E.; Sezgin, E.; GÖKGÖZ, MUSTAFA ŞEHSUVAR; Senol, Kazım; ŞENOL, KAZIM; Tıp Fakültesi; Genel Cerrahi Ana Bilim DalıPublication Metformin promotes apoptosis in primary breast cancer cells by downregulation of cyclin D1 and upregulation of P53 through an AMPK-alpha independent mechanism(Türk Tıp Bilimleri Dergisi, 2021-01-01) Yenmiş, Güven; Beşli, Nail; Saraç, Elif Yaprak; Emre, Fatma Sinem Hocaoğlu; Şenol, Kazım; Sultuybek, Gönul Kanıgur; ŞENOL, KAZIM; Tıp Fakültesi; Genel Cerrahi Ana Bilim Dalı; 0000-0001-6273-0664; KGQ-4411-2024Background/aim: In the present study we aimed to figure out the effect of metformin on the expression of AMPK-alpha, cyclin D1, and Tp53, and apoptosis in primary breast cancer cells (PBCCs).Materials and methods: PBCCs were treated with two doses of metformin (0 mM, 25 mM). Proliferation was determined by BrdU as-say. Real-time PCR was used to assess AMPK-alpha, cyclin D1, and Tp53 gene expressions; apoptotic indexes of PBCCs were analyzed using flow-cytometry.Results: Twenty-four-hour incubation with 25 mM metformin reduced the proliferation of PBCCs. AMPK-alpha gene expression in PBCCs was not affected by 25 mM metformin treatment compared with the control group. PBCCs treated with 25 mM metformin had lower cyclin D1 expression compared with nontreated cells; however, the difference was not statistically significant. Twenty-five mil-limolar dose of metformin increased p53 expression significantly compared with the nontreated group. The high concentration of met -formin elevated the number of annexin V-positive apoptotic cells, and the increase in the apoptotic index was statistically significant.Conclusion: Metformin can modulate cyclin D1 and p53 expression through AMPK-alpha-independent mechanism in breast cancer cells, leading to cell proliferation inhibition and apoptosis induction.Publication Retrospective analysis of prognostic factors affecting the recurrence and disease-free survival following surgical management of gastrointestinal stromal tumors(Turkish Surgical Assoc, 2020-06-01) Özdemir, Gül Dağlar; Akat, Arif Zeki; Kama, Nuri Aydın; Şenol, Kazım; ŞENOL, KAZIM; Tıp Fakültesi; 0000-0001-6273-0664Objective: The aim of this study was to evaluate the prognostic factors effecting recurrence risk and disease-free survival of the patients who were diagnosed as gastrointestinal stromal tumor after complete resection of the tumor with or without adjuvant therapy.Material and Methods: Between the years 2005 and 2013, data of 71 patients including clinical and demographic features, tumor localizations, pathologic examinations, survival and recurrence rates were enrolled into this retrospective study.Results: Male/female ratio was 1.71, and mean age was 60.27 +/- 14.65 years. Forty-two (59.2%) patients had tumor in stomach, 16 (22.5%) in small bowel, whereas 12 (16.9%) had extra-gastrointestinal system and one patient (%1.4) had rectal localization. Modified NIH risk stratification scheme categorized 9 (12.68%) patients in very low-, 12 (16.90%) in low-, 21 (29.58%) patients in moderate-and 29 (40.85%) patients in high-risk group. Twenty-four (33.8%) patients had a metastatic disease at follow-up while 13 (18.3%) patients were metastatic at admission. RO resection was successfully performed in 51 (71.8%) patients, while R1 resection in 9 (12.7%) and R2 resection in 11 (15.5%) were achieved. Mean follow-up time was 47.12 +/- 33.52 months (range, 1-171 months). Nineteen (26.8%) patients demonstrated recurrence with a mean time of 22.16 +/- 15.89 months (range, 3-57 months). During follow-up 17 (23.9%) patients were deceased. In univariate analysis, high-risk group, small bowel and extra-gastrointestinal system localization, R1-2 resection, necrosis, positive resection margin and invasion of surrounding tissues, metastatic disease and adjuvant therapy were statistically significant in terms of recurrence. Multivariate analysis presented small bowel and extra-gastrointestinal system localization, R2 resection, mitoses count, invasion and adjuvant therapy as independent prognostic risk factors affecting disease-free survival rates.The 1,3 and 5 years of disease-free survival rates of the patients were 89.6%, 75.4%, 64.3%, respectively.Conclusion: As mentioned in the literature, the mainstay of curative therapy of gastrointestinal stromal tumor is surgery. In our study, not only small bowel, extra-gastrointestinal system localization and invasion of surrounding tissues by tumor, but also R2 resection that complicate the local control of the disease were represented as independent adverse prognostic factors for disease-free survival. Unfavourable clinical outcomes of adjuvant therapy over the disease-free survival was linked to higher tumor stage with metastatic disease and emphasized that prospective trials with more cases should be practiced.